Can a once-weekly shot protect joints in hemophilia a? new study aims to find out.

NCT ID NCT05181618

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 4 times

Summary

This Phase IV study is testing emicizumab (Hemlibra) in 136 people aged 13 to 70 with moderate or severe hemophilia A who do not have inhibitors. The goal is to see if this drug, given as a shot under the skin, can improve joint health, increase physical activity, and enhance overall well-being compared to their previous treatment. Participants will be followed for up to 36 months, with regular checks on joint status, bleeding rates, and daily activity using a wearable tracker.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Emicizumab (Hemlibra)
What this could lead to: If successful, this study could show that emicizumab helps protect joints and improves daily life for people with hemophilia A, offering a more convenient treatment option.
What could go wrong: This is an open-label, single-arm study, so results may be biased. It is also a Phase IV trial, meaning the drug is already approved, so the focus is on refining use rather than a breakthrough. Risks include thromboembolic events and injection site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A moderately severe hemophilia A severe hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE HEMOPHILIA A SEVERE HEMOPHILIA A

Contacts and locations

Locations

AOU Careggi

Florence, Tuscany, 50134, Italy
AOU Federico II

Naples, Campania, 80131, Italy
Akdeniz Uni School of Medicine

Antalya, 07059, Turkey (Türkiye)
Aziza Othmana Hospital

Tunis, Tunisia
CHU Farhat Hached

Sousse, 4000, Tunisia
Charité Universitätsklinikum Berlin

Berlin, 13353, Germany
Complejo Hospitalario Universitario A Coruña (CHUAC)

A Coruña, 15006, Spain
Ege Uni Medical School

Izmir, 35100, Turkey (Türkiye)
Gazi Universitesi Tip Fakultesi

Ankara, 06500, Turkey (Türkiye)
Hamilton Health Sciences Corporation

Hamilton, Ontario, L9H 2B7, Canada
Hospital Regional Universitario Carlos Haya

Málaga, 29010, Spain
Hospital Universitario Vall de Hebron

Barcelona, 08035, Spain
Hospital Universitario la Paz

Madrid, 28046, Spain
Hospital das Clinicas - UNICAMP

Campinas, São Paulo, 13083-878, Brazil
Hospital das Clínicas Faculdades Médicas de Ribeirão Preto

Ribeirão Preto, São Paulo, 14051-140, Brazil
Hospital de la Santa Creu i Sant Pau

Barcelona, 08025, Spain
Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique

Rabat, 10090, Morocco
IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Lombardy, 20122, Italy
Istanbul University Cerrahpasa Medical Faculty

Istanbul, 34098, Turkey (Türkiye)
Manchester University NHS Foundation Trust (MFT)

Manchester, M13 9WL, United Kingdom
Oklahoma Children's Hospital ? Jimmy Everest Center

Oklahoma City, Oklahoma, 73104, United States
Orthopaedic Institute for Children

Los Angeles, California, 90007, United States
Policlinico Univ. A. Gemelli

Rome, Lazio, 00168, Italy
St Thomas Westminster

London, SE1 7EH, United Kingdom
University Clinical Centre of Serbia

Belgrade, 11000, Serbia
University of Miami Medical Center

Miami, Florida, 33136, United States
Universitätsklinikum Bonn

Bonn, 53127, Germany
Észak-Pesti Centrumkórház - Honvédkórház

Budapest, 1134, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.